Private Meeting Evaluates NIDA Researchers' Skills and Performance
Published Date: 3/18/2025
Notice
Summary
The National Institute on Drug Abuse (NIDA) is holding a closed virtual meeting on May 6, 2025, to review and evaluate the skills and performance of its researchers. This meeting affects scientists working on drug abuse research and helps ensure top-quality work without sharing private details publicly. No money changes are announced, but the meeting keeps NIDA’s research sharp and trustworthy.
No Economic Impacts Identified for this Document
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-17899, Proposed Collection; 60-Day Comment Request; Assurance (Interinstitutional, Foreign, and Domestic) and Annual Report (Office of the Director)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the Office of Laboratory Animal Welfare (OLAW) in the Office of Extramural Research (OER) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-17687, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review at the NIH is holding several closed virtual meetings in October 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets, ensuring fair and confidential decisions. Scientists applying for grants in genetics, molecular sciences, oral health, and cancer research are the ones affected, with no direct cost changes announced.
2026-17438, Center For Scientific Review; Notice of Closed Meetings
The NIH's Center for Scientific Review is holding several closed virtual meetings in late September 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets, affecting researchers applying for funding. No direct money changes are announced, but these reviews decide who gets research grants.
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
Previous / Next Documents
Previous: 2025-04428, National Institute on Aging; Notice of Closed Meeting
The National Institute on Aging is holding a private virtual meeting on April 3, 2025, to review important grant applications. This meeting affects researchers seeking funding and keeps sensitive info safe. No money changes are announced, but decisions could impact future aging research projects.
Next: 2025-04430, National Heart, Lung, and Blood Institute; Notice of Closed Meeting
The National Heart, Lung, and Blood Institute is holding a closed virtual meeting on April 28-29, 2025, to review important grant applications. This meeting affects researchers seeking funding and keeps sensitive info private. No money changes now, but decisions made here will shape future research support.